Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

    Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

    Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

      Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat

      Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.

        Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?

        Smart Beta ETF report for FDRR

          Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

          Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

            AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

            AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

              Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

              Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

                Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?

                Style Box ETF report for PFM

                  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

                  Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

                    Sweta Killa headshot

                    Should OShares FTSE U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?

                    Style Box ETF report for OUSA

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

                      The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay

                        Mark Vickery headshot

                        Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley

                        Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Honeywell (HON) and Morgan Stanley (MS).

                          Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

                          Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

                            J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

                            Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

                              Swarup Gupta headshot

                              Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress

                              The Dow experienced a particularly volatile week as earnings results took center stage.

                                Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

                                Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

                                  3 Dividend ETFs With High Inflows in April

                                  Consider these three dividend ETFs to fend off growing market uncertainty.

                                    Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better

                                    Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.

                                      New Construction Data, Q1 Earnings In Focus

                                      New Construction Data, Q1 Earnings In Focus

                                        Mark Vickery headshot

                                        Tax Day Not So Taxing (for Corporations, Housing)

                                        Strength in Q1 earnings season, at least in these early stages, has helped bolster market indexes. This continues ahead of Tuesday's market open.

                                          J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                                          J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                                            J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View

                                            J&J (JNJ) beat estimates for both earnings and sales in the first quarter of 2018. It maintained the previously issued earnings guidance for 2018 while increasing the sales range.

                                              Tracey Ryniec headshot

                                              5 of the Best Big Cap Earnings Charts

                                              These big cap companies almost always beat the estimate on earnings but will that change in 2018?

                                                Here's Why Geron Stock Surged More Than 90% in 6 Months

                                                Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

                                                  Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                                                  The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.